



PATENTS
Attorney Docket No. ABX-AE2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Applicants : Liise-anne Pirofski et al.
Application No. : 10/556,018 Confirmation No. : 4518
Filed : November 7, 2005
For : COMPOSITIONS AND METHODS FOR TREATMENT OF
CRYPTOCOCCOSIS
Group Art Unit : Not Yet Assigned
Examiner : Not Yet Assigned

New York, New York 10020
June 20, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants
hereby make the following documents of record in the above-
identified patent application:

U.S. Patent Documents

Patent No.	Date	Patentee(s)
4,399,216	08/16/1983	Axel, R., et al
4,510,245	04/09/1985	Cousens, L., et al.
4,634,665	06/06/1987	Axel, R., et al.
4,740,461	04/26/1988	Kaufman, R.

Patent No.	Date	Patentee(s)
4,912,040	03/27/1990	Kaufman, R., et al.
4,959,455	09/25/1990	Clark, S., et al.
4,968,615	11/06/1990	Koszinowski, U., et al.
5,168,062	12/01/1992	Stinski, M.
5,179,017	01/12/1993	Axel, R., et al.
5,741,957	04/21/1998	Deboer, H., et al.
5,750,172	05/12/1998	Meade, H.
5,756,687	05/26/1998	Denman, J., et al.
5,827,690	10/27/1998	Meade., H. et al.
5,916,771	06/29/1999	Hori, N., et al.
5,939,598	08/17/1999	Kucherlapati, R., et al.
5,985,615	11/16/1999	Jakobovits, A., et al.
5,998,209	12/07/1999	Jakobovits, A., et al.
6,075,181	06/13/2000	Kucherlapati, R., et al.
6,091,001	07/18/2000	Jakobovits, A., et al.
6,114,598	09/05/2000	Kucherlapati, R., et al.
6,130,364	10/10/2000	Jakobovits, A., et al.

FOREIGN PATENT DOCUMENTS

Publication No.	Date	Applicant(s)
0 216 846	01/10/1990	Kenten, J., et al.
0 256 055	01/23/1987	Wilson, R., et al.
0 323 997	07/22/1988	Bebbington, C.
WO 00/037504	06/29/2000	Hanson, D., et al.
WO 00/09560	02/24/2000	Gallo, M., et al.
WO 91/10741	07/25/1991	Kucherlapati, R., et al.
WO 94/02602	02/03/1994	Kucherlapati, R., et al.
WO 96/33735	10/31/1996	Kucherlapati, R., et al.
WO 96/34096	10/31/1996	Kucherlapati, R., et al.
WO 98/16654	04/23/1998	Hori, N., et al.
WO 98/24893	06/11/1998	Jakobovits, A., et al.
WO 98/50433	11/12/1998	Jakobovits, A., et al.
WO 99/45031	09/10/1999	Davis, C., et al.
WO 99/53049	10/21/1999	Davis, C., et al.

Other Documents

BOWIE, J., et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> 253:164-170 (1991)
CHANG, Q., et al. "Structure-Function Relationships for Human Antibodies to Pneumococcal Capsular Polysaccharide from Transgenic Mice with Human Immunoglobulin Loci," <i>Infection and Immunity</i> 70:4977-86 (2002)
CHOTHIA, C., Lesk, A., "Canonical structures for the hypervariable regions of immunoglobulins," <i>J. Mol. Biol.</i> 196:901-917 (1987)
CHOTHIA, C., et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> 342:877-883 (1989)
FLEURIDOR, R., et al. "A Cryptococcal Capsular Polysaccharide Mimotope Prolongs the Survival of Mice with <i>Cryptococcus neoformans</i> Infection," <i>Journal of Immunology</i> 166:1087-96 (2001)
FLEURIDOR, R., et al. "Quantitative and Qualitative Differences in the Serum Antibody Profiles of Human Immunodeficiency Virus-Infected Persons with and without <i>Cryptococcus neoformans</i> Meningitis," <i>The Journal of Infectious Diseases</i> 180:1526-35 (1999)
GREEN, L. and Jakobovits, A., "Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes," <i>J. Exp. Med.</i> 188:483-495 (1998)
GREEN, L., et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," <i>Nature Genet.</i> 7:13-21 (1994)
HOLLIGER, P., et al. "'Diabodies': Small bivalent and bispecific antibody fragments," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:6444-48 (1993)
JOHNSON, G. Wu, T., "Kabat Database and its applications: future directions," <i>Nucleic Acids Research</i> 29:205-206 (2001)
KAUFMAN, R. and Sharp, P., "Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene," <i>Journal of Molecular Biology</i> 159-601-21 (1982)
KOSTELNY, S., et al. "Formation of a bispecific antibody by the use of leucine zippers," <i>The Journal of Immunology.</i> 148:1547-53 (1992)
MAITTA, R., et al. "Immunogenicity and Efficacy of <i>Cryptococcus neoformans</i> Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice," <i>Infection and Immunity</i> 72:196-208 (2004)

MCCORMICK, L., et al. "Bispecific antibodies overcome the opsonin-receptor mismatch of cystic fibrosis in vitro: restoration of neutrophil-mediated phagocytosis and killing of <i>Pseudomonas aeruginosa</i> ," <i>J. Immunol.</i> 158:3474-82 (1997)
MENDEZ, M., et al. "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," <i>Nature Genet.</i> 15:146-56 (1997)
MUKHERJEE, J., et al. "Molecular Characterization of the Humoral Responses to <i>Cryptococcus neoformans</i> Infection and Glucuronoxylomannan-Tetanus Toxioid Conjugate Immunization," <i>J. Exp. Med.</i> 177:1105-1116 (1993).
PIROFSKI, L., et al. "Analysis of Human Monoclonal Antibodies Elicited by Vaccination with a <i>Cryptococcus neoformans</i> Glucuronoxylomannan Capsular Polysaccharide Vaccine," <i>Infection and Immunity</i> 63:3005-14 (1995)
RUSSELL, N., et al. "Production of Protective Human Antipneumococcal Antibodies by Transgenic Mice with Human Immunoglobulin Loci," <i>Infection and Immunity</i> 68:1820-26 (2000)
SONGSIVILAI, S., et al., "Bispecific antibody: a tool for diagnosis and treatment of disease," <i>Clin. Exp. Immunol.</i> , 79:315-21 (1990)
THORNTON, J., et al., "Protein structure. Prediction of progress at last," <i>Nature</i> 354:105-106 (1991)
TRAUNECKER, A., et al. "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>The EMBO Journal</i> 10:3655-59 (1991)
TRAUNECKER, A., et al., "Janusin: new molecular design for bispecific reagents," <i>Intl. J. Cancer Suppl.</i> 7:51-52 (1992).
ZHANG, J., et al. "Peptide Epitopes Recognized by a Human Anti-Cryptococcal Glucuronoxylomannan Antibody," <i>Infection and Immunity</i> 65:1158-64 (1997)
ZHONG, Z., et al. "Molecular and Functional Characteristics of a Protective Human monoclonal Antibody to Serotype 8 <i>Streptococcus pneumoniae</i> Capsular Polysaccharide," <i>Infection and Immunity</i> 67:4119-27 (1999)

Copies of the aforementioned documents are listed on the accompanying Form PTO SB/08 and copies of the non-US patent documents are enclosed herewith.

Applicants request that these documents be (1) fully considered by the Patent and Trademark Office during the examination of this application; and (2) printed on any patent which may issue on this application. Applicants request that a copy of Form PTO SB/08, as considered and initialed by the Examiner, be returned with the next communication.

Consideration of the foregoing in relation to this patent application is respectfully requested.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants

FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000
Fax: (212) 596-9090

I hereby certify that this correspondence
is being deposited with the US Postal Service
as First Class Mail in an envelope Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

June 20, 2006


Signature of person Signing



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/556,018		
		Filing Date	November 7, 2005		
		First Named Inventor	Liise-anne Pirofski et al.		
		Art Unit	Not Yet Assigned		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	3	Attorney Docket Number	ABX-AE2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		4,399,216	08/16/1983	Axel, R., et al	
		4,510,245	04/09/1985	Cousens, L., et al.	
		4,634,665	06/06/1987	Axel, R., et al.	
		4,740,461	04/26/1988	Kaufman, R.	
		4,912,040	03/27/1990	Kaufman, R., et al.	
		4,959,455	09/25/1990	Clark, S., et al.	
		4,968,615	11/06/1990	Koszinowski, U., et al.	
		5,168,062	12/01/1992	Stinski, M.	
		5,179,017	01/12/1993	Axel, R., et al.	
		5,741,957	04/21/1998	Deboer, H., et al.	
		5,750,172	05/12/1998	Meade, H.	
		5,756,687	05/26/1998	Denman, J., et al.	
		5,827,690	10/27/1998	Meade, H., et al.	
		5,916,771	06/29/1999	Hori, N., et al.	
		5,939,598	08/17/1999	Kucherlapati, R., et al.	
		5,985,615	11/16/1999	Jakobovits, A., et al.	
		5,998,209	12/07/1999	Jakobovits, A., et al.	
		6,075,181	06/13/2000	Kucherlapati, R., et al.	
		6,091,001	07/18/2000	Jakobovits, A., et al.	
		6,114,598	09/05/2000	Kucherlapati, R., et al.	
		6,130,364	10/10/2000	Jakobovits, A., et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		0 216 846	01/10/1990	Kenten, J., et al.		
		0 256 055	01/23/1987	Wilson, R., et al.		
		0 323 997	07/22/1988	Bebington, C.		
		WO 00/037504	06/29/2000	Hanson, D., et al.		
		WO 00/09560	02/24/2000	Gallo, M., et al.		
		WO 91/10741	07/25/1991	Kucherlapati, R., et al.		
		WO 94/02602	02/03/1994	Kucherlapati, R., et al.		
		WO 96/33735	10/31/1996	Kucherlapati, R., et al.		
		WO 96/34096	10/31/1996	Kucherlapati, R., et al.		
		WO 98/16654	04/23/1998	Hori, N., et al.		
		WO 98/24893	06/11/1998	Jakobovits, A., et al.		
		WO 98/50433	11/12/1998	Jakobovits, A., et al.		
		WO 99/45031	09/10/1999	Davis, C., et al.		
		WO 99/53049	10/21/1999	Davis, C., et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/556,018
				Filing Date	November 7, 2005
				First Named Inventor	Liise-anne Pirofski et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	ABX-AE2

--	--	--	--	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BOWIE, J., et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> 253:164-170 (1991)	
		CHANG, Q., et al. "Structure-Function Relationships for Human Antibodies to Pneumococcal Capsular Polysaccharide from Transgenic Mice with Human Immunoglobulin Loci," <i>Infection and Immunity</i> 70:4977-86 (2002)	
		CHOTHIA, C., Lesk, A., "Canonical structures for the hypervariable regions of immunoglobulins," <i>J. Mol. Biol.</i> 196:901-917 (1987)	
		CHOTHIA, C., et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> 342:877-883 (1989)	
		FLEURIDOR, R., et al. "A Cryptococcal Capsular Polysaccharide Mimotope Prolongs the Survival of Mice with <i>Cryptococcus neoformans</i> Infection," <i>Journal of Immunology</i> 166:1087-96 (2001)	
		FLEURIDOR, R., et al. "Quantitative and Qualitative Differences in the Serum Antibody Profiles of Human Immunodeficiency Virus-Infected Persons with and without <i>Cryptococcus neoformans</i> Meningitis," <i>The Journal of Infectious Diseases</i> 180:1526-35 (1999)	
		GREEN, L. and Jakobovits, A., "Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes," <i>J. Exp. Med.</i> 188:483-495 (1998)	
		GREEN, L., et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," <i>Nature Genet.</i> 7:13-21 (1994)	
		HOLLIGER, P., et al. "Diabodies": Small bivalent and bispecific antibody fragments," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:6444-48 (1993)	
		JOHNSON, G. Wu, T., "Kabat Database and its applications: future directions," <i>Nucleic Acids Research</i> 29:205-206 (2001)	
		KAUFMAN, R. and Sharp, P., "Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene," <i>Journal of Molecular Biology</i> 159:601-21 (1982)	
		KOSTELNY, S., et al. "Formation of a bispecific antibody by the use of leucine zippers," <i>The Journal of Immunology</i> . 148:1547-53 (1992)	
		MAITTA, R., et al. "Immunogenicity and Efficacy of <i>Cryptococcus neoformans</i> Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice," <i>Infection and Immunity</i> 72:196-208 (2004)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/556,018
				Filing Date	November 7, 2005
				First Named Inventor	Liise-anne Pirofski et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	ABX-AE2


		MCCORMICK, L., et al. "Bispecific antibodies overcome the opsonin-receptor mismatch of cystic fibrosis in vitro: restoration of neutrophil-mediated phagocytosis and killing of <i>Pseudomonas aeruginosa</i> ," <i>J. Immunol.</i> 158:3474-82 (1997)	
		MENDEZ, M., et al. "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," <i>Nature Genet.</i> 15:146-56 (1997)	
		MUKHERJEE, J., et al. "Molecular Characterization of the Humoral Responses to <i>Cryptococcus neoformans</i> Infection and Glucuronoxylomannan-Tetanus Toxioid Conjugate Immunization," <i>J. Exp. Med.</i> 177:1105-1116 (1993).	
		PIROFSKI, L., et al. "Analysis of Human Monoclonal Antibodies Elicited by Vaccination with a <i>Cryptococcus neoformans</i> Glucuronoxylomannan Capsular Polysaccharide Vaccine," <i>Infection and Immunity</i> 63:3005-14 (1995)	
		RUSSELL, N., et al. "Production of Protective Human Antipneumococcal Antibodies by Transgenic Mice with Human Immunoglobulin Loci," <i>Infection and Immunity</i> 68:1820-26 (2000)	
		SONGSIVILAI, S., et al., "Bispecific antibody: a tool for diagnosis and treatment of disease," <i>Clin. Exp. Immunol.</i> , 79:315-21 (1990)	
		THORNTON, J., et al., "Protein structure. Prediction of progress at last," <i>Nature</i> 354:105-106 (1991)	
		TRAUNECKER, A., et al. "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>The EMBO Journal</i> 10:3655-59 (1991)	
		TRAUNECKER, A., et al., "Janusin: new molecular design for bispecific reagents," <i>Intl. J. Cancer Suppl.</i> 7:51-52 (1992).	
		ZHANG, J., et al. "Peptide Epitopes Recognized by a Human Anti-Cryptococcal Glucuronoxylomannan Antibody," <i>Infection and Immunity</i> 65:1158-64 (1997)	
		ZHONG, Z., et al. "Molecular and Functional Characteristics of a Protective Human monoclonal Antibody to Serotype 8 <i>Streptococcus pneumoniae</i> Capsular Polysaccharide," <i>Infection and Immunity</i> 67:4119-27 (1999)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 <p>TRANSMITTAL FORM</p> <p>(to be used for all correspondence after initial filing)</p>	Application Number	10/556,018
	Filing Date	November 7, 2005
	First Named Inventor	Liise-anne Rirofski et al.
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	ABX-AE2

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Postcard; PTO/SB/08a/b Form; copies of all non-US patent documents listed thereon.
Remarks The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 06-1075. I have enclosed a duplicate copy of this sheet.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	FISH & NEAVE IP GROUP OF ROPES & GRAY LLP		
Signature			
Printed name	Jane T. Gunnison		
Date	June 20, 2006	Reg. No.	38,479

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Isatta B. Smith	Date	6/20/06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.